Test article concentrations in the hERG assay: Losses through the perfusion, solubility and stability
- 28 February 2009
- journal article
- Published by Elsevier in Journal of Pharmacological and Toxicological Methods
- Vol. 59 (1) , 29-34
Abstract
No abstract availableKeywords
This publication has 16 references indexed in Scilit:
- Preclinical Torsades-de-Pointes Screens: Advantages and limitations of surrogate and direct approaches in evaluating proarrhythmic riskPharmacology & Therapeutics, 2008
- ILSI-HESI cardiovascular safety subcommittee initiative: Evaluation of three non-clinical models of QT prolongationJournal of Pharmacological and Toxicological Methods, 2006
- Utility of hERG Assays as Surrogate Markers of Delayed Cardiac Repolarization and QT SafetyToxicologic Pathology, 2006
- Oral Erythromycin and the Risk of Sudden Death from Cardiac CausesNew England Journal of Medicine, 2004
- Experiences in method development for the analysis of in vitro study solutions for contentJournal of Pharmacological and Toxicological Methods, 2004
- Relationships between preclinical cardiac electrophysiology, clinical QT interval prolongation and torsade de pointes for a broad range of drugs: evidence for a provisional safety margin in drug developmentCardiovascular Research, 2003
- Cardiotoxicity of macrolides, ketolides and fluoroquinolones that prolong the QTc intervalExpert Opinion on Drug Safety, 2002
- A mechanism for the proarrhythmic effects of cisapride (Propulsid): high affinity blockade of the human cardiac potassium channel HERGFEBS Letters, 1997
- HERG, a Primary Human Ventricular Target of the Nonsedating Antihistamine TerfenadineCirculation, 1996
- A molecular basis for cardiac arrhythmia: HERG mutations cause long QT syndromeCell, 1995